Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study

  title={Pregnancy outcomes following cabergoline treatment: extended results from a 12‐year observational study},
  author={A. Colao and R. Abs and D. G. B{\'a}rcena and P. Chanson and W. Paulus and D. Kleinberg},
  journal={Clinical Endocrinology},
  • A. Colao, R. Abs, +3 authors D. Kleinberg
  • Published 2008
  • Medicine
  • Clinical Endocrinology
  • Objective  Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. Because hyperprolactinaemia is a significant cause of infertility in women, cabergoline and other dopamine agonists are frequently prescribed to reduce prolactin levels and restore normal menses. They are usually discontinued shortly after the patient becomes pregnant. Although cabergoline has been used to treat hyperprolactinaemia since the mid‐1990s, safety data related to maternal and foetal exposure to this… CONTINUE READING
    75 Citations
    High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy
    • 14
    Prolactinoma and pregnancy: From the wish of conception to lactation.
    • D. Maiter
    • Medicine
    • Annales d'endocrinologie
    • 2016
    • 13
    Prolactinomas and pregnancy
    • 18
    Cabergoline therapy for Macroprolactinoma during pregnancy: A case report
    • 3
    • PDF
    Prolactinomas, cabergoline, and pregnancy
    • 30
    2012 update in the treatment of prolactinomas.
    • 22


    Bromocriptine in pregnancy: Safety aspects
    • 102
    Management of prolactinomas during pregnancy.
    • M. Molitch
    • Medicine
    • The Journal of reproductive medicine
    • 1999
    • 84
    Pregnancy outcome after cabergoline treatment in early weeks of gestation.
    • 138
    Current treatment issues in female hyperprolactinaemia.
    • P. Crosignani
    • Medicine
    • European journal of obstetrics, gynecology, and reproductive biology
    • 2006
    • 72
    Prolactinomas and Pregnancy
    • 110